ConductScience.org, home

Paper25985403

The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs.

Martin M and 15 others. AIDS, 2015. Cited by 89 papers, by iCite.

Cite this record

ConductScience Library. The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. Papers, record 25985403. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25985403

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs.
PubMed
Journal
AIDS
PubMed
Year
2015
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
89
iCite
Relative citation ratio, by iCite
3.94
iCite
Revised in PubMed
2022-03-11
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Martin MMichael
2Vanichseni SSuphak
3Suntharasamai PPravan
4Sangkum UUdomsak
5Mock PAPhilip A
6Leethochawalit MManoj
7Chiamwongpaet SSithisat
8Curlin MEMarcel E
9Na-Pompet SSupawadee
10Warapronmongkholkul AAnchalee
11Kittimunkong SSomyot
12Gvetadze RJRoman J
13McNicholl JMJanet M
14Paxton LALynn A
15Choopanya KKachit
16Bangkok Tenofovir Study GroupGroup

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
HIV InfectionsMajor topic
Medication AdherenceMajor topic
Pre-Exposure ProphylaxisMajor topic
Substance Abuse, IntravenousMajor topic
Adult
Anti-HIV Agents
Double-Blind Method
Female
Humans
Male
Medical Records
Middle Aged
Risk Assessment
Tenofovir
Young Adult

Source PubMed

Download CSV of topics

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00119106Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, ThailandBackgroundYesClinicalTrials.gov
NCT04523519PrEP Intervention for People Who Inject Substances and Use MethamphetamineBackgroundClinicalTrials.gov

Download CSV of trials

Cited by68

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 89 citations.

PMIDTitleJournalYearIn PapersSource
42778687Modelling the tail-phase pharmacokinetics of long-acting cabotegravir and rilpivirine from early pregnancy to postpartum at steady state.J Pharmacokinet Pharmacodyn2026https://conductscience.org/library/papers/42778687PubMed
41678009Interest in Long-Acting PrEP by Methamphetamine Use Among Men Who Have Sex with Men in Four Western US Cities.AIDS Behav2026https://conductscience.org/library/papers/41678009PubMed
41419251Oral PrEP continuation rates among key populations in Nigeria: a retrospective cohort study of a large-scale HIV prevention programme.BMJ Glob Health2025https://conductscience.org/library/papers/41419251PubMed
41312653Informal PrEP use in Greece: The long, hard road to formal programmatic implementation.HIV Med2026https://conductscience.org/library/papers/41312653PubMed
41082154Digital Interventions for Stimulant Use Among People Living with HIV: A Narrative Review.Curr HIV/AIDS Rep2025https://conductscience.org/library/papers/41082154PubMed
40672761Willingness to Take Long-Acting Injectable Preexposure Prophylaxis (PrEP) and Preference for PrEP Modalities Among People Who Inject Drugs in Washington, DC.Open Forum Infect Dis2025https://conductscience.org/library/papers/40672761PubMed
40406373
Interest in Long-Acting Preexposure Prophylaxis (PrEP) Among Men at Risk for Human Immunodeficiency Virus Who Use Methamphetamine Participating in a Daily, Oral PrEP Adherence Trial in San Francisco, California.
Open Forum Infect Dis2025https://conductscience.org/library/papers/40406373PubMed
40244556Disparities in United States Nationwide County-Level PrEP Rate and PrEP to Need Ratio During the COVID-19 Pandemic.J Racial Ethn Health Disparities2026https://conductscience.org/library/papers/40244556PubMed
40222706Oral pre-exposure prophylaxis (PrEP) receipt and persistence among opioid-dependent people who inject drugs initiating PrEP for HIV prevention.J Subst Use Addict Treat2025https://conductscience.org/library/papers/40222706PubMed
40057242Implementing a pre-exposure prophylaxis (PrEP) promotion intervention among persons who inject drugs: Perspectives from community and research implementation partners.J Subst Use Addict Treat2025https://conductscience.org/library/papers/40057242PubMed
39781235The prevalence of HIV pre-exposure prophylaxis (HIV-PrEP) use and HIV-PrEP-to-need ratio in nine Canadian provinces, 2018-2021.Can Commun Dis Rep2025https://conductscience.org/library/papers/39781235PubMed
39104432Exploring the harm reduction paradigm: the role of Board-Certified Psychiatric Pharmacists.Ment Health Clin2024https://conductscience.org/library/papers/39104432PubMed
39030884Patterns of daily oral HIV PrEP adherence among people who inject drugs in Ukraine: an analysis of biomarkers.J Int AIDS Soc2024https://conductscience.org/library/papers/39030884PubMed
38722201User Experience of Persons Using Ingestible Sensor-Enabled Pre-Exposure Prophylaxis to Prevent HIV Infection: Cross-Sectional Survey Study.JMIR Mhealth Uhealth2024https://conductscience.org/library/papers/38722201PubMed
38290644"PrEPping" women's healthcare providers: motivational interviewing to support ending the HIV epidemic.Am J Obstet Gynecol2024https://conductscience.org/library/papers/38290644PubMed
38032345A Decade of HIV Preexposure Prophylaxis (PrEP): Overcoming Access Barriers in the United States Through Expanded Delivery.Public Health Rep2024https://conductscience.org/library/papers/38032345PubMed
37898146
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
Lancet HIV2023https://conductscience.org/library/papers/37898146PubMed
37732092The use of oral HIV pre-exposure prophylaxis among people who inject drugs: barriers, and recommendations.Front Public Health2023https://conductscience.org/library/papers/37732092PubMed
37335757Sexually transmitted infections in Spain: Current status.Rev Esp Quimioter2023https://conductscience.org/library/papers/37335757PubMed
36962766Awareness and willingness to use HIV oral pre-exposure prophylaxis among people who inject drugs in Dar es Salaam, Tanzania: A cross-sectional survey.PLOS Glob Public Health2022https://conductscience.org/library/papers/36962766PubMed

See all 68 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25985403

GET https://conductscience.org/api/papers/v1/25985403/cited_by?page=2